RECRUITING

Letermovir (Prevymis) for CMV in Kidney and Pancreas Transplant Recipients

Talk to us

Conditions

Cytomegalovirus InfectionsKidney Transplant InfectionPancreas Transplant

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

This study is designed to assess how effective letermovir is in preventing recurrence of cytomegalovirus (CMV) infection in adult kidney or kidney/pancreas transplant recipients who are UW Health patients. Participants will be in the study for about 6 months.

Official Title

An Interventional Study of Letermovir for Secondary Prophylaxis After Treatment of Cytomegalovirus Infection in High Risk (D+/R-) Kidney and Kidney/Pancreas Transplant Recipients

Quick Facts

Study Start:2024-08-08
Study Completion:2026-09
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT06407232

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * undergone kidney or simultaneous kidney/pancreas transplant
  2. * high-risk CMV serostatus (D+/R-) at time of transplant
  3. * develop CMV viremia that necessitates treatment per our institutional protocol (enrolled in the CMV stewardship monitoring initiative)
  4. * demonstrate proven or presumptive lack of CMI, either by CMI testing or risk factor screening
  5. * able to provide informed consent to participate
  1. * contraindication to letermovir or its excipients
  2. * develop ganciclovir-resistant CMV infection
  3. * currently participating in any study involving the administration of a CMV vaccine or another CMV investigational agent
  4. * unable or unwilling, in the opinion of the Investigator, to comply with the protocol
  5. * pregnant or breastfeeding

Contacts and Locations

Study Contact

Margaret Jorgenson, PharmD, BCTXP
CONTACT
(608) 262-2122
mrgebarski@wisc.edu
Sandesh Parajuli, MBBS
CONTACT
(608) 262-5420
sparajuli@medicine.wisc.edu

Principal Investigator

Margaret Jorgenson, PharmD, BCTXP
PRINCIPAL_INVESTIGATOR
University of Wisconsin, Madison

Study Locations (Sites)

UW Hospital and Clinics
Madison, Wisconsin, 53792
United States

Collaborators and Investigators

Sponsor: University of Wisconsin, Madison

  • Margaret Jorgenson, PharmD, BCTXP, PRINCIPAL_INVESTIGATOR, University of Wisconsin, Madison

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2024-08-08
Study Completion Date2026-09

Study Record Updates

Study Start Date2024-08-08
Study Completion Date2026-09

Terms related to this study

Additional Relevant MeSH Terms

  • Cytomegalovirus Infections
  • Kidney Transplant Infection
  • Pancreas Transplant